Rankings
▼
Calendar
CTMX Q3 2018 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CTMX
CytomX Therapeutics, Inc.
$822M
Q3 2018 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$13M
-48.2% YoY
Gross Profit
$13M
100.0% margin
Operating Income
-$23M
-185.3% margin
Net Income
-$23M
-187.3% margin
EPS (Diluted)
$-0.53
QoQ Revenue Growth
-41.4%
Cash Flow
Operating Cash Flow
-$6M
Free Cash Flow
-$7M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$483M
Total Liabilities
$325M
Stockholders' Equity
$158M
Cash & Equivalents
$260M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$13M
$24M
-48.2%
Gross Profit
$13M
$24M
-48.2%
Operating Income
-$23M
-$11M
-110.2%
Net Income
-$23M
-$10M
-128.7%
Revenue Segments
License And Service
$3M
100%
← FY 2018
All Quarters
Q4 2018 →